SUBSCRIBE
SUBSCRIBE

Merck & Co.

  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
213 E Grand Ave, South San Francisco, CA
33 Avenue Louis Pasteur, Boston, MA
320 Bent St, Cambridge, MA
NEWS
Merck Invests $20 Million into a Texas IT Hub That is Expected to Employ 600
Job Trends
Texas Officials Lure Life Sciences Companies Like Merck & Co., Which is Expected to Employ 600
July 24, 2017
 · 
3 min read
What You Need to Know About Merck & Co.'s Fearless CEO Ken Frazier
Job Trends
Corning, Merck & Co. and Pfizer to Invest $4 Billion and Create 4,000 New Jobs in the U.S.
July 21, 2017
 · 
3 min read
What You Missed: Nippon Fine Chemical Formed Human Barricade to Stop FDA Employee
Drug Development
Patient Deaths Prompt the FDA to Suspend Three of Merck & Co.'s Keytruda Trials
July 6, 2017
 · 
3 min read
Drug Development
Can Merck & Co. And Novartis AG’s Surprise Heart Drug Success Translate To Blockbuster Sales?
June 29, 2017
 · 
1 min read
Merck & Co.'s Alzheimer's Contender Wows in Human Clinical Trial
Policy
Merck & Co. Becomes Victim of Massive Ransomware Cyber Attack
June 28, 2017
 · 
3 min read
Merck & Co.'s Alzheimer's Contender Wows in Human Clinical Trial
Drug Development
Merck & Co.'s Midas Touch Continues as Heart Drug Succeeds Where Pfizer, Eli Lilly and Roche’s Failed
June 27, 2017
 · 
2 min read
Biotech Vets Launch Arrakis With $38 Million and Will be Helmed By Biogen Alum Michael Gilman
Business
UK Charity to Use $638 Million Cash From Merck & Co.'s Blockbuster Keytruda to Back R&D
June 15, 2017
 · 
3 min read
3 Biotechs That Could be Taken Out This Quarter
Drug Development
Why Drug Giants Like Merck & Co. and AstraZeneca PLC Scientists are Looking in the Toilet for New Cancer Treatments
June 14, 2017
 · 
2 min read
Merck & Co.'s Alzheimer's Contender Wows in Human Clinical Trial
Drug Development
Deaths Force Merck & Co. to Halt Enrollment for Blood Cancer Studies
June 13, 2017
 · 
2 min read
Load More
JOBS
IN THE PRESS
Pharm Country
Merck Publishes Corporate Responsibility Report
September 20, 2018
 · 
5 min read
Business
Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-8201 in Combination with KEYTRUDA® (pembrolizumab) in HER2 Expressing Breast and HER2 Expressing or HER2 Mutant Lung Cancers
September 20, 2018
 · 
6 min read
Drug Development
IMV Inc. Announces Early Positive Results from Phase 2 Clinical Trial of Lead Candidate DPX-Survivac in Combination with Merck’s Keytruda® in Patients with DLBCL
September 19, 2018
 · 
6 min read
Business
Accenture and Merck Collaborate with Amazon Web Services to Launch a Research Platform to Drive Innovation in Drug Discovery and Scientific Research
September 17, 2018
 · 
4 min read
FDA
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Monotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Patients Whose Tumors Express PD-L1 (TPS ≥1%)
September 12, 2018
 · 
24 min read
Business
IMV Inc. Announces Phase 2 Basket Trial in Collaboration with Merck to Evaluate DPX-Survivac in Combination with KEYTRUDA® Across Five Solid Tumor Indications
September 11, 2018
 · 
4 min read
Drug Development
Merck’s ZERBAXA® (ceftolozane and tazobactam) Met Primary Endpoints of Non-Inferiority Compared to Meropenem in Pivotal Phase 3 Study of Adult Patients with Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
September 11, 2018
 · 
8 min read
Pharm Country
Data from Merck’s Leading Lung Cancer Research Program with KEYTRUDA® (pembrolizumab) to be Presented at IASLC 19th World Conference on Lung Cancer
September 6, 2018
 · 
24 min read
Business
BioAscent appoints new Directors of Chemistry and Biosciences to lead integrated drug discovery services
September 5, 2018
 · 
2 min read
Policy
Eisai and Merck Announce China National Medical Products Administration (NMPA) Approval of LENVIMA® (lenvatinib) for Treatment of Unresectable Hepatocellular Carcinoma (HCC)
September 5, 2018
 · 
25 min read
Load More